| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2502-256
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2500-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2015-1081
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2015-0065 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N15-1031
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0024
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0602
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0686
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56966
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-12 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-23
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-071 |
| filingDate |
2008-06-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2010-08-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2010528658-A |
| titleOfInvention |
Selective cell therapy for the treatment of renal failure |
| abstract |
An isolated renal cell population collected from differentiated kidney cells grown in vitro is provided. Renal cells may include paratubule stromal cells and preferably produce erythropoietin (EPO). Renal cells may be selected based on EPO production. A method of generating an isolated EPO-producing cell population is also provided, and administration of this population to a patient, whereby the cells produce EPO in vivo, thereby producing EPO production in a patient in need of treatment. A method of treating renal disease that results in a decrease is provided. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2018085996-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2021100428-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2014533113-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2018148909-A |
| priorityDate |
2007-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |